Oral Health Manifestations of GLP-1 and Dual GIP/GLP-1 Receptor Agonist Therapies (Semaglutide and Tirzepatide): A Review
Abstract
The global surge in glucagon-like peptide-1 (GLP-1) receptor agonists and dual incretin therapies, such as semaglutide (Ozempic) and tirzepatide (Mounjaro), has introduced distinct secondary oral complications widely recognized as "Ozempic Mouth" and "Ozempic Teeth." Immediate therapy triggers severe salivary hypofunction and accelerated gastric reflux across both drug classes, while long-term maintenance promotes profound structural damage, including severe enamel decay, dental restoration failure, and the facial soft tissue hollowing known as "Ozempic Face." Dental practitioners must recognize these shared clinical manifestations and employ targeted remineralization, acid neutralization, and pre-surgical protocols to protect dental health during metabolic treatment.

